Fig 1: LV-Chop-shRNA promotes survival of tunicamycin aggravated pulmonary fibrosis by bleomycin. A Schematic of the experimental study in C57BL/6 mice. shChop, LV-Chop-shRNA; TM, tunicamycin; bleo, bleomycin. B Kaplan–Meier analysis for TM/bleo mice treated with or without shCHOP. n = 10 biological independent animals per group. C Gating strategy for flowcytometric sorting of EpCAM positive epithelial cells of mouse lung. D mRNA level of CHOP and Shh of sorted epithelial cells relative to control. Each dot represents cells from an independent mouse. n = 10 per group. E Representative immunofluorescence images on mouse lung. AECII was labeled with pro-SPC (green) and Shh (red). Bar = 50 μm. F Quantification of the percentage of Shh positive AECII in mouse lung. Each dot represents cell numbers in one field. n = 10 per group
Fig 2: LR-MSC in bleomycin-induced pulmonary fibrosis (BLM) mirrors the behavior of which in IPF. A Immunofluorescence of BLM and normal lungs show the colocalization of mouse LR-MSC marker Sca1 and myofibroblast marker α-SMA. Arrows indicate positive staining of α-SMA in LR-MSC. Arrowheads indicate the parabronchial distribution of LR-MSC during homeostasis. B Immunofluorescence of BLM and normal lungs show the expression of CHOP in LR-MSC. C Gating strategy for analyzing the expression of EpCam in Sca1+CD45−CD31− cells by FACS. D Isolated LR-MSC morphology was revealed by conventional light microscopy after 3 days of culture. E Schematic of the workflow used to isolate LR-MSC during homeostasis (Saline) and fibrosis (Bleomycin) for subsequent experiments. F Counts of isolated LR-MSC in each normal or BLM C57BL/6 mouse. G Western blot shows the expression of ER stress and fibrosis-associated proteins in isolated LR-MSC
Supplier Page from Abcam for Anti-EpCAM antibody [EPR20533-63] (PE)